CLL-Lymphoma US Focus Meeting

Course Information

Course Instructor

Author
 

CLL-LYMPHOMA Focus Meeting 2023

$1,000.00

Registration fee

Complimentary coupon code for supporters can be added at checkout.

 
Continue

Opening Introduction to the meeting – Ryan Fitzpatrick, CEO, MD Education​

Ryan Fitzpatrick, CEO, MD Education​

Session I

Richters syndrome​ – Debbie Stephens – University of Utah
SCT in CLL​ – Chitra Hosing – MD Anderson Cancer Center
Frontline therapy​ – Susan O’Brien – University of California Irvine Medical Center
Treatment of patients with P53 aberrations​ – Nitin Jain – MD Anderson Cancer Center
Session I – Panel Discussion  

Session II​

CART in CLL​ – David Maloney – Fred Hutchinson Cancer Center
Small molecule combinations​ – Nitin Jain – MD Anderson Cancer Center
Covalent BTK inhibitors comparison – Kerry Rogers – The Ohio State University​
Non-covalent BTK inhibitors​ – Jennifer Woyach – The Ohio State University
Session II -Panel Discussion ​

Session III

Toxicities of Targeted Agents​ – Alessandra Ferrajoli – MD Anderson Cancer Center, Houston, Texas
Real World Data with small molecules ​- Danielle Brander – Duke University School of Medicine
Session III – Panel Discussion

Session IV

Supportive care in CLL, vaccines etc​ – Clare Sun – National Heart, Lung and Blood Institute
Splicing alterations in CLL pathogenesis​ – Lili Wang – City of Hope
Monoclonal B cell lymphocytosis risk of disease progression, and other clinical consequences​ – Sameer Parikh – Mayo Clinic
Session IV – Panel Discussion

Session V

Cell free DNA (at diagnosis for disease burden assessment, for molecular classification, for minimal residual disease monitoring)​ – Dai Chihara – MD Anderson Cancer Centre
Molecular classification of lymphomas (DLBCL, FL)​ – Sandeep Dave – Duke University School of Medicine
Molecular classification of lymphomas (FL, PTCL, MCL)​ – Sandeep Dave – Duke University School of Medicine
Intergrating Biomakers into Clinical Trials and Clinical Practice​ – Christopher Flowers – MD Anderson Cancer Center
Session V –  Panel Discussion

Session VI​

CAR T cells in lymphoma – What to do now and what’s next Results of 1L trials, challenges in SOC 2L therapy, new trials in 3L+)​ – Sattva Neelapu – MD Anderson Cancer Center
Clinical management of CAR T (approaches to toxicity management, outpatient CAR T)​ – Caron Jacobson – Dana Farber Cancer Institute
Bispecific Antibodies vs. CAR T cells in FL and DLBCL​ – Paolo Strati – MD Anderson Center
Emerging trials in lymphoma Alliance/industry (DLBCL, other indolent)​ –  John Leonard – Weill Cornell Medicine
Session VI​ – Panel Discussion
Genentech Expert Discussion – John Leonard ​
Genentech Expert Discussion – Elizabeth Brem  ​
Panel Discussion

Session VII

Emerging trials in lymphoma SWOG/industry (HL, PTCL)​ – Elizabeth Brem – UCI Health Cancer Center
Management strategies for MCL – where should we go next? (transplant and CAR T, intensive fixed duration therapy, continuous oral approaches)​ – Julie Vose – University of Nebraska
Current and future strategies in T-cell lymphomas (chemotherapy, should transplant be an option, novel agents)​ – Swami Iyer – MD Anderson Cancer Center
Session VII – Panel Discussion

Session VIII

Approaches in first line Hodgkin lymphoma (approaches to reduce therapy intensity/duration, late complications/survivorship)​ – Ranjana Advani – Stanford University
Unresolved Trial Strategies for FL (Early POD, low risk disease)​ – Paolo Strati – MD Anderson Center
Novel approaches for relapsed HL (new uses of approved agents, new agents)​ – Swetha Kambhampati – City of Hope
Session VIII – Panel Discussion

Estancia Hotel
La Jolla, California

Agenda

It is our pleasure to invite you to participate in this one-of-a-kind event.

If you need additional information please contact us at: office@md-education.com

MD Education
4/4a Bloomsbury Square,
London, WC1A 2RP

MD Education USA LLC
4600 140th Avenue North Suite,
180 Clearwater, Florida 33762